2673271-78-6
2673271-78-6
Chemical Structure
Nezutatug
Synonym(s): HMBD-001
- CAS No.: 2673271-78-6
- Formula:N/A
- Molecular Weight:(144.89 kDa)
SMILES: [Nezutatug]
Biological Activity: Nezutatug (HMBD-001) is a humanized IgG1 monoclonal antibody inhibitor targeting HER3. Nezutatug inhibits the dimerization of HER3 and inhibits the growth, proliferation and other activities of tumor cells. Nezutatug is promising for research of cancers, such as pancreatic cancer and non-small cell lung cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Nezutatug | 99.9% | Nezutatug (HMBD-001) is a humanized IgG1 monoclonal antibody inhibitor targeting HER3. Nezutatug inhibits the dimerization of HER3 and inhibits the growth, proliferation and other activities of tumor cells. Nezutatug is promising for research of cancers, such as pancreatic cancer and non-small cell lung cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Pavlakis N, et al. 88TiP A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling[J]. Annals of Oncology, 2023, 34: S1501.
- [2]. Idowu O, et al. 688P Pharmacokinetics of HMBD-001, a human monoclonal antibody targeting HER3, a CRUK first-in-human phase I trial in patients with advanced solid tumours[J]. Annals of Oncology, 2023, 34: S480.
Keywords
